In this respect, we found OU and Digo as FDA-approved drugs that reduce ERα intracellular content and cell proliferation in ductal carcinoma cells (MCF-7 cells), in a previous drug screen [18]. Here, ESR1 is linked to breast ductal adenocarcinoma.